ID   KCB9
AC   CVCL_D3ZJ
DR   Wikidata; Q127382416
RX   PubMed=32144432;
RX   PubMed=34275013;
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; HGNC:1008; BCL9 + HGNC; HGNC:6997; MEF2D; Name(s)=MEF2D-BCL9 (PubMed=32144432; PubMed=34275013).
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   17Y5M
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 19-12-24; Version: 3
//
RX   PubMed=32144432; DOI=10.1007/s00280-020-04045-9;
RA   Goto H., Yoshino Y., Ito M., Nagai J.-i., Kumamoto T., Inukai T.,
RA   Sakurai Y., Miyagawa N., Keino D., Yokosuka T., Iwasaki F.,
RA   Hamanoue S., Shiomi M., Goto S.;
RT   "Aurora B kinase as a therapeutic target in acute lymphoblastic
RT   leukemia.";
RL   Cancer Chemother. Pharmacol. 85:773-783(2020).
//
RX   PubMed=34275013; DOI=10.1007/s00280-021-04321-2;
RA   Goto H., Yoshino Y., Ito M., Nagai J.-i., Kumamoto T., Inukai T.,
RA   Sakurai Y., Miyagawa N., Keino D., Yokosuka T., Iwasaki F.,
RA   Hamanoue S., Shiomi M., Goto S.;
RT   "Correction to: Aurora B kinase as a therapeutic target in acute
RT   lymphoblastic leukemia.";
RL   Cancer Chemother. Pharmacol. 88:1055-1056(2021).
//